Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Burlington Stores Inc (BURL) Price & Performance

Amphastar Pharmaceuticals IncTrade
Burlington Stores IncTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Burlington Stores Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Burlington Stores Inc trades at $359.42 (market cap $23.38B). The key difference: Burlington Stores Inc is far larger — about 27.1× Amphastar Pharmaceuticals Inc's market cap, and Burlington Stores Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

AMPHBURL
Market Cap
$863.95M$23.38B
Sector
HealthConsumer Cyclical
52-Week High
$30.81$372.19
52-Week Low
$16.87$242.43
Enterprise Value
$1.26B$28.51B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Burlington Stores Inc

Burlington Stores (BURL) trades at $368.96, showing slight weakness with a 0.59% decline but remains near recent highs. The stock maintains strong technical momentum with bullish moving averages and trades above key support levels. Fundamentally, the company demonstrates robust earnings performance with three consecutive quarterly beats and improving profitability margins. Recent news highlights Burlington's successful smaller-store strategy driving sales productivity and upgraded analyst ratings.

The outlook remains positive with 94% analyst buy ratings and a $367 consensus target. Growth catalysts include continued store expansion and operational efficiency gains, though risks include competitive retail pressures and potential consumer spending volatility. The stock's premium valuation requires sustained execution to justify current levels.

Returns comparison

Trailing returns across standard periods

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Burlington Stores Inc

Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.

Read more on BURL